Formulation and Evaluation of Delayed Release Coated Tablet of Dalfampridine for the Treatment of Multiple Sclerosis
DOI:
https://doi.org/10.22270/ajprd.v12i4.1436Abstract
The study aimed to develop delayed release coated tablets of Dalfampridine for treating multiple sclerosis. Dalfampridine core tablets were prepared using wet granulation method with various excipients. Pre-compression parameters and flow characteristics were evaluated to ensure smooth tablet production. Post-compression studies included weight variation, thickness, hardness, friability, drug content, and In-vitro drug release. Coating was applied to the core table formulation using a 5% coating solution consisting of Eudragit L100-55, PEG-600, talc, color concentrate, IPA, and acetone. Coating parameters such as inlet temperature, spraying rate, and pan rotation were optimized using a 23 factorial design. The stability study confirmed the formulation's stability at room temperature and 40°C/75% RH for one month. The coated tablets showed no drug release in acidic environments (pH 1.2) but released the drug in intestinal environments (pH 6.8). Formulation E2, coated under specific conditions i.e. inlet temperature of 500c, spay rate of 2ml/min and pan rotation of 15 rpm was identified as the best formulation based on % weight gain, coating process efficiency, and release time in the intestine.
Downloads
References
1. Vuyyala G, Dasari V, Krantikumar P, Godasu SK, Raju P. Stability Indicating Rp-Hplc Method Development Of Drug Used In Multiple Sclerosis. Journal of Engineering Sciences. 2023;14(01).
Kim J, De Jesus O. Medication routes of administration.
Palshikar P, Sharma A, Chauhan CS, Kamble R. Preparation and evaluation of enteric coated tablet of sodium valproate. Int J Res Pharm Chem. 2013;3(3):583-90.
Hussan SD, Santanu R, Verma P, Bhandari V. A review on recent advances of enteric coating. IOSR J Pharm. 2012 Nov;2(6):05-11.
Salawi A. Pharmaceutical Coating and Its Different Approaches, a Review. Polymers (Basel). 2022 Aug 15;14(16):3318. doi: 10.3390/polym14163318. PMID: 36015575; PMCID: PMC9415771.
Simon Gaisford. Dosage form design and manufacture: Pharmaceutical Preformulation. Aulton’s Pharmaceutical London: Elsvier; 2013: 367-368
Patil A, Payghan SA, Disouza JI. Formulation and evaluation of enteric coated tablets of azithromycin dehydrate. Int J Chem Tech Res. 2011;3(3):1479-84.
Chhater S, Rajesh K, Kshitij A, Nema RK. Development and evaluation of enteric coated tablet containing diclofenac sodium. International journal of pharmaceutical sciences and nanotechnology. 2009;2:443-9.
Pawar PS, Saleem MA. Formulation and evaluation of oral colon targeted tablet of budesonide. Pharm Lett. 2013;5(3):1-2.
Nagarajan B, Manoharan G. Stability-Indicating HPLC Method for the determination of related substances in Lansoprazole Intermediate. International Journal of Engineering Science Technologies. 2022;6(3):20-7.
Porter SC. Coating of pharmaceutical dosage forms. In Remington 2021 Jan 1 (pp. 551-564). Academic Press.
Heinämäki J, Ruotsalainen M, Lehtola VM, Antikainen O, Yliruusi J. Optimization of aqueous-based film coating of tablets performed by a side-vented pan-coating system.
Zaid AN, Qaddomi A. Development and stability evaluation of enteric coated Diclofenac sodium tablets using Sureteric. Pakistan journal of pharmaceutical sciences. 2012 Jan 1;25(1).
Mehetre GD, Cheke RS, Shrikhande VN. Formulation and in-vitro evaluation of enteric coated tablet incorporating rabeprazole. Journal of Drug Delivery and Therapeutics. 2020 Apr 15;10(2-s):50-7.
Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010 May 1;67(3):217-23.
WHO-GMP and ICH Stability Testing Guidelines for Drug Products. The Pharmaceutical Sciences-Pharma Pathway;2.72-2.79.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Yukta K. Mhaskey, Dr. Vikrant P. Wankhade, Aditi V. Tikait, Dr. Sandeep C. Atram, Nishant N. Bobade, Dr. S. D. Pande
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.